State Street Corp Buys 62,692 Shares of ChromaDex Co. (NASDAQ:CDXC)

State Street Corp lifted its position in ChromaDex Co. (NASDAQ:CDXC) by 11.3% during the third quarter, HoldingsChannel.com reports. The fund owned 618,028 shares of the company’s stock after purchasing an additional 62,692 shares during the period. State Street Corp’s holdings in ChromaDex were worth $2,256,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. The Manufacturers Life Insurance Company bought a new position in ChromaDex during the second quarter worth about $31,000. Merriman Wealth Management LLC acquired a new stake in shares of ChromaDex during the second quarter worth about $32,000. FMR LLC bought a new position in shares of ChromaDex during the 3rd quarter valued at about $55,000. SG Americas Securities LLC acquired a new position in shares of ChromaDex in the 3rd quarter valued at approximately $61,000. Finally, MetLife Investment Management LLC increased its stake in ChromaDex by 39.3% during the 3rd quarter. MetLife Investment Management LLC now owns 18,114 shares of the company’s stock worth $66,000 after purchasing an additional 5,115 shares in the last quarter. Institutional investors own 15.41% of the company’s stock.

Analyst Ratings Changes

CDXC has been the topic of a number of research reports. StockNews.com raised shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, December 25th. Roth Mkm boosted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright increased their target price on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th.

ChromaDex Stock Down 2.8 %

Shares of CDXC opened at $5.30 on Thursday. ChromaDex Co. has a twelve month low of $1.36 and a twelve month high of $7.97. The stock has a market capitalization of $404.83 million, a P/E ratio of 530.53 and a beta of 2.15. The company has a 50 day moving average of $6.21 and a 200-day moving average of $4.22.

ChromaDex (NASDAQ:CDXC) last released its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The business had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. During the same quarter last year, the firm earned ($0.01) earnings per share. On average, sell-side analysts anticipate that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.64% of the stock is currently owned by corporate insiders.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.